Arrowhead Pharmaceuticals, Inc. Q2 FY26 Earnings Analysis

- REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch. - Approximately 85% of prescriptions are from APOC3 class-naive patients, indicating growth via newly identified FCS patients. - Prescription growth shows geographic breadth across the U.S., suggesting scalable patient identification and durable demand. - Early patient persistence and satisfaction data are encouraging for sustained usage. - Plans to expand REDEMPLO into the severe hypertriglyceridemia (SHTG) market with SHASTA-3 and SHASTA-4 Phase III data readout expected in Q3 2026. - Anticipated clinical data readouts (ARO-DIMER-PA, ARO-MAPT) and additional obesity/NASH programs could drive pipeline growth and future revenue. - The company aims to leverage commercial capabilities established for FCS to support future launches, including potential SHTG and HoFH indications. - Balance sheet strength (~$1.8 billion cash and investments) provides flexibility to fund expansion and commercialization efforts.

- No specific future guidance on earnings, operating earnings, profits, or EPS was provided during the call. - Q2 FY26 reported a net loss of $132.7 million ($0.93 per share) compared to net income in prior year due to one-time transaction revenue in 2025. - Commercial momentum for REDEMPLO continues with growing prescriptions, supporting expansion. - Upcoming key catalysts in H2 2026 (SHASTA-3/4, MURI-3 readouts, ARO-DIMER-PA, ARO-MAPT data) expected to drive pipeline value. - Large cash position (~$1.8 billion) provides financial flexibility for R&D and commercialization. - Management emphasizes focus on advancing clinical pipeline and expanding commercial footprint, implying potential long-term growth. - No explicit earnings or EPS projections were disclosed; future financial performance will depend on clinical successes and market adoption.

- Arrowhead conducted its largest fundraising ever in the recent quarter, raising over $1 billion through public offerings of convertible senior notes and common stock, strengthening the balance sheet to support ongoing and future investments. - Capital investment is focused on advancing clinical development programs, including Phase III studies for plozasiran in severe hypertriglyceridemia (SHTG) and early-stage programs like dimer and MAPT. - Strategic investments also include expanding commercial infrastructure to support REDEMPLO and future potential launches (e.g., SHTG and HoFH treatments). - The company entered an exclusive worldwide license agreement with Madrigal for ARO-PNPLA3 to advance this asset via partnership rather than internal capital allocation. - Capital allocation favors wholly owned pipeline advancement while selectively partnering programs (e.g., C3 and Factor B) to optimize ROI and resource distribution. - No immediate mention of significant new capital projects outside clinical development and commercialization expansion.

- In Q2 FY2026, Arrowhead completed its largest fundraising ever, raising over $1 billion. - This included approximately $850 million net from January 2026 financing transactions. - The financing comprised concurrent offerings of $700 million in 0% coupon convertible senior notes and $230 million in common stock. - Both offerings were several times oversubscribed, indicating strong investor confidence. - No specific mention of plans for new future fundraising through debt or equity was provided in the call. - The company emphasized that this strong balance sheet provides significant financial flexibility to support ongoing clinical development and potential commercialization.

- More than 400 prescriptions for REDEMPLO have been written since its launch. - Approximately 30 new prescriptions are being written each week currently. - Over 10% of these prescriptions are from patients switching from a competitor's APOC3 inhibitor. - Prescriptions require full adjudication with payers before becoming paid claims. - No specific mention of a detailed current or expected orderbook volume or pending orders beyond prescription data was provided.